NVDA   420.09 (+2.80%)
CGC   16.08 (-1.53%)
BABA   261.13 (+1.34%)
GE   6.61 (-3.65%)
TSLA   1,395.00 (+2.13%)
AMD   57.42 (+7.47%)
ACB   11.73 (-3.62%)
GILD   74.95 (-0.87%)
DIS   116.67 (+0.01%)
BAC   22.73 (-1.64%)
BA   173.70 (-3.54%)
NVDA   420.09 (+2.80%)
CGC   16.08 (-1.53%)
BABA   261.13 (+1.34%)
GE   6.61 (-3.65%)
TSLA   1,395.00 (+2.13%)
AMD   57.42 (+7.47%)
ACB   11.73 (-3.62%)
GILD   74.95 (-0.87%)
DIS   116.67 (+0.01%)
BAC   22.73 (-1.64%)
BA   173.70 (-3.54%)
NVDA   420.09 (+2.80%)
CGC   16.08 (-1.53%)
BABA   261.13 (+1.34%)
GE   6.61 (-3.65%)
TSLA   1,395.00 (+2.13%)
AMD   57.42 (+7.47%)
ACB   11.73 (-3.62%)
GILD   74.95 (-0.87%)
DIS   116.67 (+0.01%)
BAC   22.73 (-1.64%)
BA   173.70 (-3.54%)
NVDA   420.09 (+2.80%)
CGC   16.08 (-1.53%)
BABA   261.13 (+1.34%)
GE   6.61 (-3.65%)
TSLA   1,395.00 (+2.13%)
AMD   57.42 (+7.47%)
ACB   11.73 (-3.62%)
GILD   74.95 (-0.87%)
DIS   116.67 (+0.01%)
BAC   22.73 (-1.64%)
BA   173.70 (-3.54%)
Log in

NASDAQ:INCYIncyte Stock Price, Forecast & News

$107.76
-0.51 (-0.47 %)
(As of 07/9/2020 03:56 PM ET)
Add
Compare
Today's Range
$105.59
Now: $107.76
$109.11
50-Day Range
$90.81
MA: $99.99
$108.93
52-Week Range
$62.48
Now: $107.76
$110.36
Volume45,767 shs
Average Volume1.50 million shs
Market Capitalization$23.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.05
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Read More
Incyte logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$2.48 per share
Book Value$12.06 per share

Profitability

Net Income$446.91 million

Miscellaneous

Employees1,456
Market Cap$23.42 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

Incyte (NASDAQ:INCY) Frequently Asked Questions

How has Incyte's stock been impacted by COVID-19 (Coronavirus)?

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INCY stock has increased by 49.9% and is now trading at $107.76. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Incyte?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Incyte.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Incyte.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) announced its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($2.86) EPS for the quarter, missing analysts' consensus estimates of $0.31 by $3.17. The biopharmaceutical company had revenue of $568.51 million for the quarter, compared to analyst estimates of $553.24 million. Incyte had a negative net margin of 16.87% and a negative return on equity of 12.81%. The company's revenue was up 14.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.62 EPS. View Incyte's earnings history.

What price target have analysts set for INCY?

23 equities research analysts have issued 12-month price objectives for Incyte's stock. Their forecasts range from $79.00 to $124.00. On average, they anticipate Incyte's stock price to reach $100.65 in the next twelve months. This suggests that the stock has a possible downside of 6.6%. View analysts' price targets for Incyte.

Has Incyte been receiving favorable news coverage?

Media headlines about INCY stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Incyte earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Incyte.

Who are some of Incyte's key competitors?

What other stocks do shareholders of Incyte own?

Who are Incyte's key executives?

Incyte's management team includes the following people:
  • Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 59)
  • Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel
  • Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 56)
  • Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 52)
  • Ms. Christiana Stamoulis, Exec. VP & CFO (Age 48)

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by many different institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.04%), DNB Asset Management AS (0.01%), Envestnet Asset Management Inc. (0.01%), Patton Fund Management Inc. (0.00%), Symphony Financial Ltd. Co. (0.00%) and Ellevest Inc. (0.00%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View institutional ownership trends for Incyte.

Which institutional investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including Patton Fund Management Inc., and Envestnet Asset Management Inc.. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon, and Yao Wenqing. View insider buying and selling activity for Incyte.

Which institutional investors are buying Incyte stock?

INCY stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, DNB Asset Management AS, Symphony Financial Ltd. Co., and Ellevest Inc.. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Jean Jacques Bienaime. View insider buying and selling activity for Incyte.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $107.76.

How big of a company is Incyte?

Incyte has a market capitalization of $23.42 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

What is Incyte's official website?

The official website for Incyte is www.incyte.com.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.